Search results for: Chronic Diseases
Filter search results
The WHO Technical Report on the Pricing of Cancer Medicines: Missing a Central Role for Value Assessment
8 April 2019
…by use of value-based assessment of health and health-related outcomes and by value-based pricing. Additional incentives may be needed for ultra-orphan drugs in oncology and other diseases. Effective management of…
OHE Lunchtime Seminar: Incentives for R&D, Competition and Intertemporal Effects of Payment Rules for Cures
13 May 2019
…to 2 p.m. Current payment and pricing rules for pharmaceutical products do not account for intertemporal effects of cures for infectious diseases, producing a positive intertemporal externality for future generations….
We Asked, You Answered: Reflections on the First Round of MVAC Feedback
16 May 2019
…country governments in the driver’s seat to accelerate R&D for diseases that affect the world’s poor—specifically, the 10 million men, women, and children who develop tuberculosis (TB) disease each year…
Patient Preferences for Diagnostic Tests Aimed at Managing Antimicrobial Resistance
7 October 2019
…research found that patients across Europe have different preferences, which may have significant implications for the design and uptake of diagnostic tests. Antimicrobial resistance (AMR) in infectious diseases is a…
OHE Lunchtime Seminar: Personalised Medicine: Is it an oil-rush or oil-spill?
16 January 2020
…general difficulty associated with personalised medicine. Generally, complex diseases are associated multiple genetic mutations and it is clear that genetic mutations rarely map 1-2-1 to disease. Professor Alistair McGuire…
The Value of Diagnostic information (VODI) in Heart Failure – Recognising Value Beyond ‘Beats-Per-Minute’
3 December 2020
…However, common symptoms between HF and other diseases make it challenging for healthcare professionals to confirm or rule out HF. Diagnostic information is needed to diagnose HF timely and accurately,…
Cost-Effectiveness Thresholds and Expert Elicitation: a Bridge Too Far?
29 April 2021
…diseases within budgeting categories. A quarter of clinical experts stated either that they were not an expert, or only an expert in a single clinical field, and therefore lacked relevant…
Let’s talk about (health) inequalities
1 April 2022
…of action in the remit of HTA (see individual experience in Figure 1). For instance, introducing a HI modifier may be an extension of the policy for rare diseases –…
OHE’s 60th Anniversary Party – Celebrating Our Achievements and Looking Forward
21 June 2022
…knowledge in health economics has been substantial and broad, ranging from measuring the cost of diseases and the National Health System to studying whether a medicine is good value, how…